Name | Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
---|
Amyotrophic Lateral Sclerosis | 91 | 2024 | 1414 | 13.500 |
Why?
|
Neurofilament Proteins | 4 | 2022 | 318 | 0.980 |
Why?
|
Speech | 9 | 2022 | 540 | 0.910 |
Why?
|
Motor Neuron Disease | 1 | 2023 | 99 | 0.890 |
Why?
|
Disease Progression | 22 | 2024 | 13284 | 0.800 |
Why?
|
Caregivers | 3 | 2020 | 2094 | 0.720 |
Why?
|
Speech Disorders | 7 | 2022 | 189 | 0.700 |
Why?
|
Geographic Information Systems | 1 | 2020 | 281 | 0.640 |
Why?
|
Frontotemporal Dementia | 3 | 2024 | 248 | 0.610 |
Why?
|
Nerve Growth Factors | 2 | 2022 | 574 | 0.610 |
Why?
|
Travel | 2 | 2020 | 788 | 0.610 |
Why?
|
Behavior | 1 | 2020 | 561 | 0.600 |
Why?
|
Videoconferencing | 1 | 2019 | 195 | 0.580 |
Why?
|
Neurodegenerative Diseases | 5 | 2024 | 1061 | 0.570 |
Why?
|
Telemedicine | 5 | 2020 | 2872 | 0.550 |
Why?
|
Ambulatory Care Facilities | 3 | 2021 | 933 | 0.550 |
Why?
|
Neuroprotective Agents | 5 | 2022 | 941 | 0.500 |
Why?
|
Neuromuscular Diseases | 1 | 2017 | 248 | 0.500 |
Why?
|
Mesenchymal Stem Cell Transplantation | 1 | 2019 | 496 | 0.490 |
Why?
|
Clinical Trials, Phase II as Topic | 2 | 2014 | 629 | 0.480 |
Why?
|
Clinical Trials as Topic | 10 | 2023 | 7913 | 0.470 |
Why?
|
Speech Intelligibility | 5 | 2022 | 81 | 0.450 |
Why?
|
Clinical Trials, Phase III as Topic | 2 | 2014 | 841 | 0.440 |
Why?
|
Disabled Persons | 1 | 2022 | 1212 | 0.430 |
Why?
|
Herpes Zoster | 2 | 2005 | 264 | 0.420 |
Why?
|
Ceftriaxone | 1 | 2013 | 168 | 0.420 |
Why?
|
Dysarthria | 3 | 2022 | 57 | 0.410 |
Why?
|
Endpoint Determination | 2 | 2022 | 601 | 0.400 |
Why?
|
Patient Advocacy | 1 | 2013 | 353 | 0.390 |
Why?
|
Delivery of Health Care | 3 | 2019 | 5319 | 0.390 |
Why?
|
Taurochenodeoxycholic Acid | 2 | 2020 | 34 | 0.380 |
Why?
|
Phenylbutyrates | 2 | 2020 | 69 | 0.370 |
Why?
|
Spinal Cord | 5 | 2021 | 1809 | 0.350 |
Why?
|
Humans | 98 | 2024 | 744343 | 0.350 |
Why?
|
Biomedical Research | 3 | 2020 | 3309 | 0.340 |
Why?
|
Polypyrimidine Tract-Binding Protein | 1 | 2018 | 26 | 0.330 |
Why?
|
Patient Selection | 3 | 2021 | 4215 | 0.330 |
Why?
|
Research | 1 | 2017 | 1999 | 0.330 |
Why?
|
Motor Cortex | 3 | 2021 | 986 | 0.330 |
Why?
|
Motor Neurons | 5 | 2024 | 844 | 0.330 |
Why?
|
Heterogeneous-Nuclear Ribonucleoproteins | 1 | 2018 | 70 | 0.320 |
Why?
|
Brain Stem | 1 | 2013 | 846 | 0.310 |
Why?
|
Patient Care Team | 1 | 2019 | 2531 | 0.310 |
Why?
|
Immunosuppressive Agents | 2 | 2018 | 4149 | 0.300 |
Why?
|
Speech Perception | 2 | 2022 | 489 | 0.290 |
Why?
|
Referral and Consultation | 2 | 2019 | 3528 | 0.290 |
Why?
|
Speech Production Measurement | 6 | 2023 | 98 | 0.290 |
Why?
|
Cytokines | 3 | 2020 | 7322 | 0.290 |
Why?
|
Research Design | 4 | 2022 | 5987 | 0.290 |
Why?
|
Recovery of Function | 2 | 2013 | 2925 | 0.260 |
Why?
|
Activities of Daily Living | 2 | 2022 | 2418 | 0.250 |
Why?
|
Psychomotor Performance | 1 | 2013 | 1901 | 0.250 |
Why?
|
Cyclohexanecarboxylic Acids | 1 | 2005 | 141 | 0.250 |
Why?
|
Double-Blind Method | 10 | 2023 | 12026 | 0.240 |
Why?
|
Speech Therapy | 3 | 2019 | 57 | 0.240 |
Why?
|
Home Care Services | 2 | 2021 | 606 | 0.240 |
Why?
|
Disease Management | 2 | 2019 | 2459 | 0.240 |
Why?
|
Aged | 34 | 2023 | 163280 | 0.230 |
Why?
|
Amines | 1 | 2005 | 276 | 0.230 |
Why?
|
RNA Splicing | 1 | 2018 | 907 | 0.230 |
Why?
|
Middle Aged | 37 | 2023 | 213383 | 0.230 |
Why?
|
Adult | 33 | 2023 | 214055 | 0.220 |
Why?
|
Complex Regional Pain Syndromes | 1 | 2004 | 124 | 0.220 |
Why?
|
Deglutition Disorders | 2 | 2019 | 605 | 0.210 |
Why?
|
Search Engine | 1 | 2023 | 144 | 0.210 |
Why?
|
Male | 40 | 2022 | 350118 | 0.200 |
Why?
|
Pain Threshold | 1 | 2005 | 584 | 0.200 |
Why?
|
Venous Thromboembolism | 1 | 2014 | 1671 | 0.200 |
Why?
|
Cost of Illness | 2 | 2023 | 1859 | 0.200 |
Why?
|
Hyperalgesia | 1 | 2005 | 502 | 0.200 |
Why?
|
Female | 39 | 2022 | 380194 | 0.190 |
Why?
|
Phenylenediamines | 1 | 2021 | 90 | 0.190 |
Why?
|
Dysphonia | 1 | 2023 | 144 | 0.180 |
Why?
|
MAP Kinase Kinase Kinases | 1 | 2022 | 261 | 0.180 |
Why?
|
Delayed Diagnosis | 1 | 2023 | 441 | 0.180 |
Why?
|
Data Collection | 2 | 2020 | 3341 | 0.180 |
Why?
|
Cromolyn Sodium | 1 | 2019 | 87 | 0.170 |
Why?
|
Carbamates | 1 | 2021 | 196 | 0.170 |
Why?
|
gamma-Aminobutyric Acid | 1 | 2005 | 1121 | 0.170 |
Why?
|
Quinidine | 1 | 2018 | 57 | 0.170 |
Why?
|
Dextromethorphan | 1 | 2018 | 38 | 0.170 |
Why?
|
Creutzfeldt-Jakob Syndrome | 1 | 2019 | 89 | 0.170 |
Why?
|
Sick Leave | 1 | 2019 | 110 | 0.160 |
Why?
|
Parkinson Disease | 2 | 2022 | 2775 | 0.160 |
Why?
|
Hashimoto Disease | 1 | 2019 | 97 | 0.160 |
Why?
|
Transplantation, Autologous | 2 | 2022 | 2124 | 0.160 |
Why?
|
Ambulatory Care | 2 | 2019 | 2708 | 0.160 |
Why?
|
Voice Disorders | 1 | 2021 | 276 | 0.160 |
Why?
|
Self Report | 2 | 2021 | 3558 | 0.160 |
Why?
|
Riluzole | 2 | 2022 | 55 | 0.160 |
Why?
|
Nurse Practitioners | 1 | 2021 | 270 | 0.150 |
Why?
|
Dinucleotide Repeats | 1 | 2017 | 30 | 0.150 |
Why?
|
Speech-Language Pathology | 1 | 2017 | 25 | 0.150 |
Why?
|
Enteral Nutrition | 2 | 2020 | 763 | 0.140 |
Why?
|
Acoustics | 3 | 2023 | 239 | 0.140 |
Why?
|
Amino Acids, Branched-Chain | 1 | 2018 | 251 | 0.140 |
Why?
|
Reading | 1 | 2019 | 558 | 0.130 |
Why?
|
Encephalitis | 1 | 2019 | 423 | 0.130 |
Why?
|
Bradycardia | 1 | 2017 | 307 | 0.130 |
Why?
|
Tracheostomy | 1 | 2019 | 401 | 0.130 |
Why?
|
Prevalence | 4 | 2023 | 15226 | 0.130 |
Why?
|
tau Proteins | 2 | 2021 | 1868 | 0.130 |
Why?
|
Biological Specimen Banks | 1 | 2020 | 711 | 0.130 |
Why?
|
Quality of Life | 4 | 2020 | 12804 | 0.130 |
Why?
|
Anti-Bacterial Agents | 1 | 2013 | 7181 | 0.120 |
Why?
|
Early Diagnosis | 1 | 2019 | 1184 | 0.120 |
Why?
|
Histone Deacetylases | 1 | 2019 | 728 | 0.120 |
Why?
|
Housing | 1 | 2019 | 664 | 0.120 |
Why?
|
DNA Repeat Expansion | 1 | 2014 | 66 | 0.120 |
Why?
|
Demography | 2 | 2013 | 1656 | 0.120 |
Why?
|
Vital Capacity | 3 | 2022 | 925 | 0.120 |
Why?
|
RNA-Binding Protein FUS | 1 | 2014 | 72 | 0.120 |
Why?
|
Cost Savings | 1 | 2019 | 926 | 0.120 |
Why?
|
South America | 1 | 2013 | 181 | 0.120 |
Why?
|
Patient Care Planning | 1 | 2019 | 921 | 0.120 |
Why?
|
Single-Blind Method | 1 | 2017 | 1590 | 0.120 |
Why?
|
Case-Control Studies | 6 | 2020 | 21746 | 0.110 |
Why?
|
Costs and Cost Analysis | 1 | 2019 | 1681 | 0.110 |
Why?
|
Biological Products | 1 | 2022 | 860 | 0.110 |
Why?
|
Mood Disorders | 1 | 2020 | 1106 | 0.110 |
Why?
|
Hospice Care | 1 | 2020 | 672 | 0.110 |
Why?
|
MicroRNAs | 2 | 2020 | 3752 | 0.110 |
Why?
|
Treatment Outcome | 6 | 2021 | 63114 | 0.110 |
Why?
|
Registries | 3 | 2023 | 8089 | 0.110 |
Why?
|
Anti-Inflammatory Agents | 2 | 2019 | 1790 | 0.110 |
Why?
|
Metabolome | 1 | 2019 | 895 | 0.110 |
Why?
|
Guidelines as Topic | 1 | 2019 | 1405 | 0.100 |
Why?
|
G-Quadruplexes | 1 | 2014 | 162 | 0.100 |
Why?
|
Coronavirus Infections | 2 | 2020 | 3133 | 0.100 |
Why?
|
Tongue | 1 | 2015 | 406 | 0.100 |
Why?
|
Pneumonia, Viral | 2 | 2020 | 3240 | 0.100 |
Why?
|
Advance Care Planning | 1 | 2019 | 662 | 0.100 |
Why?
|
Longitudinal Studies | 4 | 2022 | 13989 | 0.100 |
Why?
|
Benzothiazoles | 1 | 2012 | 248 | 0.100 |
Why?
|
Aged, 80 and over | 10 | 2021 | 57776 | 0.100 |
Why?
|
Speech Acoustics | 2 | 2023 | 151 | 0.100 |
Why?
|
Muscular Atrophy | 1 | 2014 | 349 | 0.100 |
Why?
|
Severity of Illness Index | 5 | 2020 | 15540 | 0.100 |
Why?
|
Counseling | 1 | 2019 | 1523 | 0.100 |
Why?
|
Electric Impedance | 1 | 2015 | 729 | 0.100 |
Why?
|
Mesenchymal Stem Cells | 1 | 2022 | 1632 | 0.100 |
Why?
|
Autoantibodies | 1 | 2019 | 2035 | 0.090 |
Why?
|
Proteins | 2 | 2017 | 6103 | 0.090 |
Why?
|
Oxidative Stress | 1 | 2021 | 3086 | 0.090 |
Why?
|
United States | 7 | 2023 | 69872 | 0.090 |
Why?
|
Motor Skills | 1 | 2013 | 522 | 0.090 |
Why?
|
Time Factors | 5 | 2023 | 40075 | 0.090 |
Why?
|
Fatigue | 1 | 2017 | 1531 | 0.090 |
Why?
|
Multiple Sclerosis | 2 | 2022 | 3079 | 0.090 |
Why?
|
Health Care Costs | 1 | 2023 | 3209 | 0.090 |
Why?
|
Recombinant Fusion Proteins | 1 | 2018 | 3772 | 0.080 |
Why?
|
Pain | 1 | 2004 | 4986 | 0.080 |
Why?
|
Mitochondria | 1 | 2021 | 3520 | 0.080 |
Why?
|
Dose-Response Relationship, Drug | 4 | 2022 | 10943 | 0.080 |
Why?
|
Metabolomics | 2 | 2019 | 1484 | 0.080 |
Why?
|
Reproducibility of Results | 6 | 2022 | 19905 | 0.080 |
Why?
|
Phosphorylation | 4 | 2021 | 8436 | 0.080 |
Why?
|
Databases, Factual | 1 | 2023 | 7729 | 0.080 |
Why?
|
Prognosis | 4 | 2022 | 29063 | 0.080 |
Why?
|
Cerebral Cortex | 2 | 2021 | 5708 | 0.070 |
Why?
|
History, 20th Century | 1 | 2015 | 2740 | 0.070 |
Why?
|
Neurologic Examination | 2 | 2014 | 930 | 0.070 |
Why?
|
Brain Ischemia | 1 | 2020 | 3265 | 0.070 |
Why?
|
Neurons | 3 | 2021 | 9338 | 0.070 |
Why?
|
Cross-Sectional Studies | 4 | 2019 | 25043 | 0.070 |
Why?
|
Pandemics | 3 | 2021 | 8388 | 0.070 |
Why?
|
Pilot Projects | 1 | 2019 | 8324 | 0.070 |
Why?
|
Mutagenesis, Insertional | 1 | 2018 | 655 | 0.070 |
Why?
|
Protein Kinase Inhibitors | 1 | 2022 | 5535 | 0.070 |
Why?
|
Decision Making | 1 | 2019 | 3887 | 0.060 |
Why?
|
Cell Nucleus | 1 | 2014 | 2969 | 0.060 |
Why?
|
Pain Measurement | 2 | 2005 | 3420 | 0.060 |
Why?
|
Anxiety | 1 | 2019 | 4297 | 0.060 |
Why?
|
Drug Combinations | 2 | 2020 | 1959 | 0.060 |
Why?
|
Forecasting | 1 | 2013 | 2951 | 0.060 |
Why?
|
Inflammation | 2 | 2022 | 10638 | 0.060 |
Why?
|
Hypesthesia | 1 | 2004 | 109 | 0.060 |
Why?
|
DNA-Binding Proteins | 3 | 2024 | 9648 | 0.060 |
Why?
|
Muscle Strength | 2 | 2020 | 592 | 0.060 |
Why?
|
Anticonvulsants | 2 | 2021 | 1916 | 0.060 |
Why?
|
Incidence | 3 | 2019 | 20947 | 0.060 |
Why?
|
Prospective Studies | 3 | 2022 | 53288 | 0.060 |
Why?
|
Health Services Accessibility | 1 | 2020 | 5137 | 0.050 |
Why?
|
Linoleic Acids | 1 | 2022 | 39 | 0.050 |
Why?
|
Polyphosphates | 1 | 2022 | 18 | 0.050 |
Why?
|
Randomized Controlled Trials as Topic | 2 | 2022 | 9959 | 0.050 |
Why?
|
Inosine | 1 | 2023 | 133 | 0.050 |
Why?
|
Cohort Studies | 6 | 2021 | 40561 | 0.050 |
Why?
|
Wrist | 1 | 2024 | 224 | 0.050 |
Why?
|
Survival Rate | 2 | 2013 | 12788 | 0.050 |
Why?
|
Esters | 1 | 2022 | 210 | 0.050 |
Why?
|
Voice Quality | 1 | 2023 | 217 | 0.050 |
Why?
|
Gene Fusion | 1 | 2024 | 371 | 0.050 |
Why?
|
Retrospective Studies | 5 | 2023 | 77449 | 0.050 |
Why?
|
Antibodies, Monoclonal | 1 | 2018 | 9274 | 0.050 |
Why?
|
Culture Media, Conditioned | 1 | 2022 | 537 | 0.050 |
Why?
|
Ciprofloxacin | 1 | 2022 | 315 | 0.050 |
Why?
|
Young Adult | 7 | 2021 | 56430 | 0.050 |
Why?
|
Wheelchairs | 1 | 2020 | 77 | 0.050 |
Why?
|
Intermediate Filaments | 1 | 2020 | 175 | 0.050 |
Why?
|
Meningoencephalitis | 1 | 2020 | 78 | 0.040 |
Why?
|
Cross-Over Studies | 1 | 2005 | 2029 | 0.040 |
Why?
|
Muscle, Skeletal | 1 | 2015 | 4931 | 0.040 |
Why?
|
Injections, Spinal | 1 | 2020 | 303 | 0.040 |
Why?
|
Depression | 1 | 2019 | 7766 | 0.040 |
Why?
|
Intention to Treat Analysis | 1 | 2020 | 426 | 0.040 |
Why?
|
Upper Extremity | 1 | 2024 | 648 | 0.040 |
Why?
|
Dietary Supplements | 1 | 2011 | 3297 | 0.040 |
Why?
|
Genome-Wide Association Study | 1 | 2018 | 12261 | 0.040 |
Why?
|
Time | 1 | 2020 | 542 | 0.040 |
Why?
|
Communication Aids for Disabled | 1 | 2019 | 56 | 0.040 |
Why?
|
Extremities | 1 | 2004 | 865 | 0.040 |
Why?
|
Analgesics | 1 | 2005 | 1040 | 0.040 |
Why?
|
Epidemiologic Studies | 1 | 2021 | 676 | 0.040 |
Why?
|
Adamantane | 1 | 2019 | 173 | 0.040 |
Why?
|
Carbon Radioisotopes | 1 | 2019 | 577 | 0.040 |
Why?
|
Computers, Handheld | 1 | 2020 | 208 | 0.040 |
Why?
|
Stroke | 1 | 2020 | 9981 | 0.040 |
Why?
|
Predictive Value of Tests | 1 | 2014 | 15076 | 0.040 |
Why?
|
Ventilators, Mechanical | 1 | 2020 | 292 | 0.040 |
Why?
|
Neuralgia | 1 | 2004 | 570 | 0.040 |
Why?
|
Methylprednisolone | 1 | 2019 | 387 | 0.040 |
Why?
|
Antibody Formation | 1 | 2022 | 1402 | 0.040 |
Why?
|
Neuromuscular Junction | 1 | 2019 | 398 | 0.040 |
Why?
|
Spirometry | 1 | 2020 | 864 | 0.040 |
Why?
|
Drug Administration Schedule | 1 | 2005 | 4933 | 0.040 |
Why?
|
Animals | 8 | 2022 | 168757 | 0.040 |
Why?
|
Uric Acid | 1 | 2023 | 766 | 0.040 |
Why?
|
Risk | 2 | 2019 | 9687 | 0.030 |
Why?
|
Hydroxamic Acids | 1 | 2019 | 494 | 0.030 |
Why?
|
Delphi Technique | 1 | 2019 | 778 | 0.030 |
Why?
|
Follow-Up Studies | 2 | 2018 | 39050 | 0.030 |
Why?
|
Patients | 1 | 2022 | 900 | 0.030 |
Why?
|
Fluorescent Antibody Technique | 1 | 2020 | 2505 | 0.030 |
Why?
|
Epitopes | 1 | 2022 | 2571 | 0.030 |
Why?
|
Fee-for-Service Plans | 1 | 2021 | 694 | 0.030 |
Why?
|
Immune System | 1 | 2021 | 805 | 0.030 |
Why?
|
Skin Diseases | 1 | 2004 | 1065 | 0.030 |
Why?
|
Respiratory Function Tests | 1 | 2020 | 1616 | 0.030 |
Why?
|
Fatal Outcome | 1 | 2020 | 1850 | 0.030 |
Why?
|
Interleukin-2 | 1 | 2022 | 1904 | 0.030 |
Why?
|
Dependovirus | 1 | 2020 | 706 | 0.030 |
Why?
|
Chromatography, Liquid | 1 | 2019 | 976 | 0.030 |
Why?
|
Bayes Theorem | 1 | 2023 | 2309 | 0.030 |
Why?
|
United States Food and Drug Administration | 1 | 2023 | 1584 | 0.030 |
Why?
|
Oligonucleotides, Antisense | 1 | 2017 | 433 | 0.030 |
Why?
|
Acute Disease | 1 | 2005 | 7149 | 0.030 |
Why?
|
Phonation | 1 | 2016 | 219 | 0.030 |
Why?
|
Cell Death | 1 | 2020 | 1706 | 0.030 |
Why?
|
Myography | 1 | 2015 | 109 | 0.030 |
Why?
|
Astrocytes | 1 | 2022 | 1270 | 0.030 |
Why?
|
Cell Line, Tumor | 2 | 2021 | 16689 | 0.030 |
Why?
|
Fatty Acids | 1 | 2022 | 1809 | 0.030 |
Why?
|
Positron-Emission Tomography | 2 | 2021 | 6234 | 0.030 |
Why?
|
Induced Pluripotent Stem Cells | 2 | 2017 | 1736 | 0.030 |
Why?
|
Cells, Cultured | 3 | 2014 | 19229 | 0.030 |
Why?
|
Transcription Initiation Site | 1 | 2014 | 196 | 0.030 |
Why?
|
Fibroblasts | 2 | 2014 | 4161 | 0.030 |
Why?
|
Gene Silencing | 1 | 2020 | 1538 | 0.030 |
Why?
|
Gas Chromatography-Mass Spectrometry | 1 | 2014 | 361 | 0.030 |
Why?
|
Mice | 4 | 2022 | 81183 | 0.030 |
Why?
|
Prednisone | 1 | 2018 | 1574 | 0.030 |
Why?
|
Enzyme-Linked Immunosorbent Assay | 1 | 2020 | 3870 | 0.030 |
Why?
|
Child | 2 | 2018 | 77709 | 0.030 |
Why?
|
Adaptation, Psychological | 1 | 2023 | 2576 | 0.030 |
Why?
|
Psychometrics | 1 | 2022 | 3002 | 0.030 |
Why?
|
Statistics as Topic | 1 | 2019 | 2373 | 0.030 |
Why?
|
Blotting, Western | 1 | 2020 | 5179 | 0.030 |
Why?
|
Synapses | 1 | 2021 | 1728 | 0.030 |
Why?
|
Molecular Imaging | 1 | 2019 | 828 | 0.030 |
Why?
|
Survival Analysis | 2 | 2017 | 10252 | 0.030 |
Why?
|
Antiviral Agents | 1 | 2004 | 2987 | 0.030 |
Why?
|
Reverse Transcriptase Polymerase Chain Reaction | 1 | 2019 | 4751 | 0.030 |
Why?
|
Mass Spectrometry | 1 | 2019 | 2203 | 0.030 |
Why?
|
Patch-Clamp Techniques | 1 | 2014 | 964 | 0.020 |
Why?
|
Brain | 3 | 2019 | 26385 | 0.020 |
Why?
|
Sensitivity and Specificity | 2 | 2018 | 14722 | 0.020 |
Why?
|
Superoxide Dismutase | 1 | 2014 | 597 | 0.020 |
Why?
|
ROC Curve | 1 | 2018 | 3527 | 0.020 |
Why?
|
Genetic Vectors | 1 | 2020 | 3420 | 0.020 |
Why?
|
C-Reactive Protein | 1 | 2022 | 3778 | 0.020 |
Why?
|
Peptides | 1 | 2022 | 4409 | 0.020 |
Why?
|
RNA Polymerase II | 1 | 2014 | 551 | 0.020 |
Why?
|
Transcranial Magnetic Stimulation | 1 | 2020 | 1432 | 0.020 |
Why?
|
Leukocytes, Mononuclear | 1 | 2017 | 1836 | 0.020 |
Why?
|
Area Under Curve | 1 | 2014 | 1654 | 0.020 |
Why?
|
Feasibility Studies | 1 | 2020 | 5078 | 0.020 |
Why?
|
Brain Diseases | 1 | 2019 | 1563 | 0.020 |
Why?
|
Dopamine Agonists | 1 | 2012 | 355 | 0.020 |
Why?
|
Respiration | 1 | 2016 | 1653 | 0.020 |
Why?
|
Pyridines | 1 | 2021 | 2825 | 0.020 |
Why?
|
Movement | 1 | 2016 | 1471 | 0.020 |
Why?
|
Drug Evaluation, Preclinical | 1 | 2014 | 1375 | 0.020 |
Why?
|
Histones | 1 | 2019 | 2599 | 0.020 |
Why?
|
T-Lymphocytes, Regulatory | 1 | 2022 | 2988 | 0.020 |
Why?
|
Structure-Activity Relationship | 1 | 2014 | 3129 | 0.020 |
Why?
|
Palliative Care | 1 | 2023 | 3493 | 0.020 |
Why?
|
Adolescent | 3 | 2021 | 85781 | 0.020 |
Why?
|
Gene Expression Regulation | 2 | 2018 | 12072 | 0.020 |
Why?
|
RNA | 1 | 2017 | 2749 | 0.020 |
Why?
|
Cell Differentiation | 2 | 2014 | 11483 | 0.020 |
Why?
|
Mice, Knockout | 1 | 2022 | 14557 | 0.020 |
Why?
|
Action Potentials | 1 | 2014 | 1806 | 0.020 |
Why?
|
Analysis of Variance | 1 | 2015 | 6365 | 0.020 |
Why?
|
Amino Acid Sequence | 1 | 2018 | 13815 | 0.020 |
Why?
|
RNA Interference | 1 | 2014 | 2889 | 0.020 |
Why?
|
RNA, Small Interfering | 1 | 2014 | 3505 | 0.020 |
Why?
|
Quality Improvement | 1 | 2020 | 3749 | 0.020 |
Why?
|
RNA, Messenger | 1 | 2019 | 13033 | 0.010 |
Why?
|
Diagnosis, Differential | 1 | 2019 | 12959 | 0.010 |
Why?
|
Weight Loss | 1 | 2014 | 2622 | 0.010 |
Why?
|
Mutation | 2 | 2020 | 29786 | 0.010 |
Why?
|
Medicare | 1 | 2021 | 6566 | 0.010 |
Why?
|
Cell Line | 1 | 2017 | 15997 | 0.010 |
Why?
|
Protein Binding | 1 | 2014 | 9386 | 0.010 |
Why?
|
Algorithms | 1 | 2022 | 13881 | 0.010 |
Why?
|
Mice, Inbred C57BL | 1 | 2019 | 21827 | 0.010 |
Why?
|
Nerve Tissue Proteins | 1 | 2014 | 4462 | 0.010 |
Why?
|
Polymorphism, Single Nucleotide | 1 | 2020 | 15519 | 0.010 |
Why?
|
Risk Assessment | 1 | 2020 | 23338 | 0.010 |
Why?
|
Alzheimer Disease | 1 | 2018 | 8037 | 0.010 |
Why?
|
Phenotype | 1 | 2014 | 16365 | 0.010 |
Why?
|
Disease Models, Animal | 1 | 2014 | 18029 | 0.010 |
Why?
|
Magnetic Resonance Imaging | 1 | 2019 | 35421 | 0.010 |
Why?
|
Risk Factors | 1 | 2012 | 72290 | 0.000 |
Why?
|